Bio-Rad Laboratories has expanded its portfolio of bioanalytical antibodies, delivering advanced tools that lab managers can leverage to optimize biotherapeutic monitoring and assay reproducibility. The newly introduced monoclonal anti-idiotypic antibodies target key biologics including pertuzumab, guselkumab, canakinumab, belimumab, and emicizumab, while the novel Human IgM-FcSpyCatcher offers researchers a rapid method for IgM format switching.
These innovations support pharmacokinetic (PK) and anti-drug-antibody (ADA) testing, helping labs maintain high throughput and consistent performance across preclinical and clinical studies.
Benefits for Lab Managers:
- Facilitates assay standardization across therapeutic classes
- Increases lab efficiency with fast antibody format conversion
- Reduces variability in bioanalytical testing
- Supports compliance in regulated environments
- Extends in-house testing capabilities for biosimilar and innovator drugs
With over 250 antibody options across 45 specificities, Bio-Rad’s offering provides the flexibility lab managers need for dynamic research and diagnostic demands.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: "Bio-Rad Extends Anti-Idiotypic Antibody and SpyCatcher Reagent Ranges for Bioanalysis and Antibody Drug Development."
